MA35886B1 - Dérivés de benzylsulfanilamide utilisés comme inhibiteurs -2 mogat - Google Patents

Dérivés de benzylsulfanilamide utilisés comme inhibiteurs -2 mogat

Info

Publication number
MA35886B1
MA35886B1 MA37244A MA37244A MA35886B1 MA 35886 B1 MA35886 B1 MA 35886B1 MA 37244 A MA37244 A MA 37244A MA 37244 A MA37244 A MA 37244A MA 35886 B1 MA35886 B1 MA 35886B1
Authority
MA
Morocco
Prior art keywords
benzylsulfanilamide
mogat
inhibitors
derivatives used
compounds
Prior art date
Application number
MA37244A
Other languages
English (en)
Inventor
Maria Carmen Fernandez
Maria Rosario Gonzalez-Garcia
Lance Allen Pfeifer
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47148691&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35886(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA35886B1 publication Critical patent/MA35886B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne des composés de formule (i) ci-dessous et des analogues de ceux-ci, dans lesquels les divers groupes substituants, r1, r2, r3, r4, r5 a, et x sont décrits ; ou un sel pharmaceutique de ceux-ci ; un procédé de traitement d'un état tel que l'hypertriglycéridémie et un procédé d'obtention des composés.
MA37244A 2012-11-06 2014-07-24 Dérivés de benzylsulfanilamide utilisés comme inhibiteurs -2 mogat MA35886B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12382432 2012-11-06
PCT/US2013/022870 WO2013116075A1 (fr) 2012-01-31 2013-01-24 Dérivés de benzylsulfanilamide utilisés comme inhibiteurs -2 mogat

Publications (1)

Publication Number Publication Date
MA35886B1 true MA35886B1 (fr) 2014-12-01

Family

ID=47148691

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37244A MA35886B1 (fr) 2012-11-06 2014-07-24 Dérivés de benzylsulfanilamide utilisés comme inhibiteurs -2 mogat

Country Status (27)

Country Link
US (1) US8575352B2 (fr)
EP (1) EP2809651B1 (fr)
JP (1) JP2015511232A (fr)
KR (1) KR20140106750A (fr)
CN (1) CN104066719B (fr)
AP (1) AP2014007794A0 (fr)
AR (1) AR089771A1 (fr)
AU (1) AU2013215468A1 (fr)
BR (1) BR112014018636A8 (fr)
CA (1) CA2859995A1 (fr)
CL (1) CL2014001861A1 (fr)
CO (1) CO7010839A2 (fr)
CR (1) CR20140322A (fr)
DO (1) DOP2014000178A (fr)
EA (1) EA201491276A1 (fr)
ES (1) ES2590929T3 (fr)
GT (1) GT201400167A (fr)
HK (1) HK1199025A1 (fr)
IL (1) IL233712A0 (fr)
MA (1) MA35886B1 (fr)
MX (1) MX2014008599A (fr)
PE (1) PE20141679A1 (fr)
PH (1) PH12014501711A1 (fr)
SG (1) SG11201404106QA (fr)
TW (1) TW201343629A (fr)
WO (1) WO2013116075A1 (fr)
ZA (1) ZA201404836B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2807147A1 (fr) 2012-01-23 2014-12-03 Eli Lilly and Company Dérivés de phényle méthanesulfonamide utilisés comme inhibiteurs mgat - 2
PE20141789A1 (es) 2012-01-31 2014-11-19 Lilly Co Eli Nuevos derivados de morofolinilo utiles como inhibidores de mogat-2
AU2013341584A1 (en) 2012-11-06 2015-04-30 Eli Lilly And Company Novel benzyl sulfonamide compounds useful as MoGAT-2 inhibitors
KR20180012858A (ko) 2015-06-15 2018-02-06 엔엠디 파마 에이피에스 신경근 장애의 치료에 사용하기 위한 화합물
TWI782056B (zh) 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有ｍｇａｔ２抑制活性的縮合環衍生物
US10385028B2 (en) 2017-12-14 2019-08-20 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11730714B2 (en) 2017-12-14 2023-08-22 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11147788B2 (en) 2017-12-14 2021-10-19 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11591284B2 (en) 2017-12-14 2023-02-28 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
WO2020145369A1 (fr) 2019-01-11 2020-07-16 塩野義製薬株式会社 Dérivé de dihydropyrazolopyrazinone présentant une activité inhibitrice sur mgat2

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1659113A1 (fr) 2004-11-08 2006-05-24 Evotec AG Inhibiteurs de 11 beta hydroxy stéroid dehydrogenase type 1 (11beta-HSD1)
EP1655283A1 (fr) * 2004-11-08 2006-05-10 Evotec OAI AG Inhibiteurs de 11béta-HSD1
CN101087771A (zh) * 2004-11-10 2007-12-12 辉瑞大药厂 经取代n－磺酰基氨基苄基－2－苯氧基乙酰胺化合物
AU2005303492A1 (en) * 2004-11-10 2006-05-18 Pfizer Inc. Substituted N-sulfonylaminobenzyl-2-phenoxy acetamide compounds
JP2010502688A (ja) * 2006-09-08 2010-01-28 ファイザー・プロダクツ・インク ジアリールエーテル誘導体およびその使用
EP2078719A4 (fr) 2006-09-28 2009-11-11 Dainippon Sumitomo Pharma Co Composé ayant une structure de pyrimidine bicyclique et composition pharmaceutique comprenant le composé
JP2010509392A (ja) * 2006-11-13 2010-03-25 ファイザー・プロダクツ・インク ジアリール、ジピリジニルおよびアリール−ピリジニル誘導体ならびにその使用
CA2709784A1 (fr) * 2007-12-21 2009-07-09 University Of Rochester Procede permettant de modifier la duree de vie d'organismes eucaryotes
JP2012518597A (ja) * 2009-02-23 2012-08-16 Ｍｓｄ株式会社 ピリミジン−４（３ｈ）−オン誘導体
EP2807147A1 (fr) 2012-01-23 2014-12-03 Eli Lilly and Company Dérivés de phényle méthanesulfonamide utilisés comme inhibiteurs mgat - 2
PE20141789A1 (es) 2012-01-31 2014-11-19 Lilly Co Eli Nuevos derivados de morofolinilo utiles como inhibidores de mogat-2

Also Published As

Publication number Publication date
CL2014001861A1 (es) 2014-11-07
JP2015511232A (ja) 2015-04-16
ZA201404836B (en) 2017-08-30
EP2809651A1 (fr) 2014-12-10
WO2013116075A1 (fr) 2013-08-08
CA2859995A1 (fr) 2013-08-08
KR20140106750A (ko) 2014-09-03
EA201491276A1 (ru) 2014-10-30
BR112014018636A8 (pt) 2017-07-11
US20130197039A1 (en) 2013-08-01
MX2014008599A (es) 2014-08-22
PE20141679A1 (es) 2014-11-08
ES2590929T3 (es) 2016-11-24
BR112014018636A2 (fr) 2017-06-20
EP2809651B1 (fr) 2016-06-29
AP2014007794A0 (en) 2014-07-31
AU2013215468A1 (en) 2014-07-10
US8575352B2 (en) 2013-11-05
HK1199025A1 (en) 2015-06-19
CR20140322A (es) 2014-08-25
TW201343629A (zh) 2013-11-01
PH12014501711A1 (en) 2014-10-13
GT201400167A (es) 2015-05-28
DOP2014000178A (es) 2014-08-31
CO7010839A2 (es) 2014-07-31
IL233712A0 (en) 2014-09-30
CN104066719A (zh) 2014-09-24
CN104066719B (zh) 2016-08-24
AR089771A1 (es) 2014-09-17
SG11201404106QA (en) 2014-08-28

Similar Documents

Publication Publication Date Title
MA35886B1 (fr) Dérivés de benzylsulfanilamide utilisés comme inhibiteurs -2 mogat
MA35128B1 (fr) Nouveaux dérivés d'imidazole utiles pour le traitement de l'arthrite
MA40301A1 (fr) Composés indolecarboxamides utiles comme inhibiteurs de kinase
MA45222B1 (fr) Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA41134A (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
MA42230B1 (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA42231B1 (fr) Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA37942A2 (fr) Hétéroaryldihydropyrimidines d'acide 6-aminé pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b
MA42341B2 (fr) Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale
MA34385B1 (fr) Composés hétérocycliques condensés comme inhibiteurs de phosphodiestérases (pdes)
MA34342B1 (fr) Dérivés de la pipéridinone en tant qu'inhibiteurs de mdm2 pour le traitement du cancer
TN2015000347A1 (fr) Azabenzimidazoles servant d'inhibiteurs d'isoenzymes pde4 pour le traitement de troubles du snc et d'autres troubles
EA201990904A1 (ru) 1,3-дизамещенные производные циклобутана или азетидина в качестве ингибиторов гемопоэтической простагландин-d-синтазы
MX2013006926A (es) Compuestos y composiciones fotocromicas.
UA110647C2 (uk) Похідне азолу, спосіб його одержання, проміжна сполука і хімічний агент, призначений для застосування в сільському господарстві і садівництві, і агент для захисту промислових матеріалів
MA38865A1 (fr) Formulation comprenant un agent hypolipidémiant
MA37384B1 (fr) Nouveaux dérivés de thiénopyrimidine, leurs procédés de préparation et leurs utilisations thérapeutiques.
MA30435B1 (fr) Inhibiteurs de protéase de type nitrile spirocyclique
MA40302A1 (fr) Dérivés de carbazole
MA39707A (fr) Dérivés de 1,2-dihydro-3h-pyrrolo [1,2-c]imidazol-3-one et leur utilisation comme agents antibactériens
FR3087439B1 (fr) Procédé pour la préparation de 3α-hydroxy-5α-prégnan-20-one (brexanolone)
MX2018001991A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
MA37501B1 (fr) Composés de pyrazole utilisés en tant qu'inhibiteurs de sglt1
MX2011004088A (es) Derivado de anillo fusionado y su aplicacion medica.
EA201390374A1 (ru) Гетероциклические соединения для лечения или профилактики расстройств, вызываемых ослабленной нейротрансмиссией серотонина, норэпинефрина или допамина